Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Dr. Gabriel Mannis is Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine, and Medical Director of Stanford’s Inpatient Leukemia Service. He specializes in the treatment of acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. As a clinical scientist, Dr. Mannis divides his time between caring for patients, teaching trainees, and researching novel therapies for AML and MDS. Dr. Mannis has co-authored numerous publications on topics including AML, hematopoietic cell transplantation, and advanced care planning for patients with hematologic malignancies. Currently, Dr. Mannis serves on the National Comprehensive Cancer Network AML panel, helping to write evidence-based guidelines for how AML is best treated. He oversees the AML clinical trial portfolio at Stanford, with multiple clinical trials of novel drugs actively enrolling for both newly diagnosed and relapsed or refractory AML.
View Full Biography
Professional Summary
Education & Certifications
- Residency: UCSF Dept of Internal Medicine (2011) CA
- Board Certification: American Board of Internal Medicine, Internal Medicine (2011)
- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2014) CA
- Medical Education: University of California Davis School of Medicine (2008) CA
Administrative Appointments
- Medical Director, Stanford Hospital Inpatient Hematology Service (2021 - Present)
- Member, Stanford Cancer Institute (2019 - Present)
- Panel Member, Acute Leukemia Working Group, Southwest Oncology Group (SWOG) (2019 - Present)
- Panel Member, Acute Myeloid Leukemia Guidelines Committee, National Comprehensive Cancer Network (2019 - Present)
Publications
-
How I treat CNS lymphomas
Rubenstein, J. L., Gupta, N. K., Mannis, G. N., LaMarre, A. K., & Treseler, P. (2013). How I treat CNS lymphomas. BLOOD, 122(14), 2318–30. -
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J., Olin, R. L., … Martin, T. G. (2015). Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. BONE MARROW TRANSPLANTATION, 50(1), 40–44. -
The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care.
Mannis, G. N., McNey, L. M., Gupta, N. K., & Gross, D. M. (2016). The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care. American Journal of Hematology. -
Long-term survival in AIDS-related primary central nervous system lymphoma.
Gupta, N. K., Nolan, A., Omuro, A., Reid, E. G., Wang, C.-C. C., Mannis, G., … Rubenstein, J. L. (2016). Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology. -
Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
Nawas, M. T., Andreadis, C., Martin, T. G., Wolf, J. L., Ai, W. Z., Kaplan, L. D., … Olin, R. L. (2019). Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
Rahmat, L. T., Nguyen, A., Abdulhaq, H., Prakash, S., Logan, A. C., & Mannis, G. N. (2018). Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. CASE REPORTS IN HEMATOLOGY, 6092646. -
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., … Kantarjian, H. M. (2018). Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. NEW ENGLAND JOURNAL OF MEDICINE, 378(25), 2386–98. -
Discussion on reply to Foley et al., 'Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?'
Mannis, G. N. (2018). Discussion on reply to Foley et al., 'Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?'. CANCER GENETICS, 220, 77–78. -
Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?
Foley, N., Van Ziffle, J., Yu, J., Qi, Z., Grenert, J. P., Yeh, I., … Mannis, G. N. (2017). Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation? CANCER GENETICS, 216, 74–78. -
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy
Gupta, N. K., Wang, C.-C., Mannis, G. N., Yu, J.-P. J., & Rubenstein, J. L. (2017). Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. LEUKEMIA & LYMPHOMA, 58(11), 2748–51. -
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation
Mule, M. P., Mannis, G. N., Wood, B. L., Radich, J. R., Hwang, J., Ramos, N. R., … Hourigan, C. S. (2016). Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(11), 1974–82. -
Paraproteinemic keratopathy as the presenting sign of hematologic malignancy
Mannis, T. E., Mannis, G. N., Waterhouse, E. G., Aldave, A. J., & Rose-Nussbaumer, J. (2016). Paraproteinemic keratopathy as the presenting sign of hematologic malignancy. AMERICAN JOURNAL OF HEMATOLOGY, 91(9), 961–62. -
Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission
Mannis, G. N., Martin, T. G., Damon, L. E., Logan, A. C., Olin, R. L., Flanders, M. D., … Andreadis, C. (2016). Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. LEUKEMIA & LYMPHOMA, 57(7), 1560–66. -
Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation
Mannis, G. N., Martin, T. G., Damon, L. E., Andreadis, C., Olin, R. L., Kong, K. A., … Logan, A. C. (2016). Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(6), 1030–36. -
Inferior vena cava filter thrombosis
Byrne, M., Mannis, G. N., Nair, J., & Andreadis, C. (2016). Inferior vena cava filter thrombosis. CLINICAL CASE REPORTS, 4(2), 162–64. -
A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia
Mannis, G. N., Andreadis, C., Logan, A. C., Damon, L. E., Benet, L. Z., Ai, W. Z., … Martin, T. G. (2015). A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15(6), 377–83. -
Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing
Mannis, G. N., Fehniger, J. E., Creasman, J. S., Jacoby, V. L., & Beattie, M. S. (2013). Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing. JAMA INTERNAL MEDICINE, 173(2), 96–103. -
Maintenance Lenalidomide in Primary CNS Lymphoma.
Rubenstein, J. L., Geng, H., Vu, K., Mannis, G., Formaker, P., Hwang, J., … Damato, B. (2019). Maintenance Lenalidomide in Primary CNS Lymphoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology. -
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
Vu, K., Mannis, G., Hwang, J., Geng, H., & Rubenstein, J. L. (2019). Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. British Journal of Haematology. -
Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant.
Eckhert, E. E., Schoenbeck, K. L., Galligan, D., McNey, L. M., Hwang, J., & Mannis, G. N. (2017). Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant. Bone Marrow Transplantation, 52(6), 929–931. -
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis, G., Wu, D., Dea, T., Mauro, T., & Hsu, G. (2015). Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. American Journal of Hematology, 90(2), 179. -
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D., … Ogba, N. (2019). Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 17(6), 721–49. -
Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.
Huang, L.-W. W., Sheng, Y., Andreadis, C., Logan, A. C., Mannis, G. N., Smith, C. C., … Olin, R. L. (2019). Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia.
Gelfand, J. M., Greenfield, A. L., Barkovich, M., Mendelsohn, B. A., Van Haren, K., Hess, C. P., & Mannis, G. N. (2019). Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia. Brain : a Journal of Neurology. -
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., … Stone, R. M. (2019). Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. -
Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
Maakaron, J. E., Ozga, M. P., Mannis, G. N., Pulley, W., Foster, M. C., Zeidner, J. F., & Mims, A. S. (2020). Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia. Annals of Hematology. -
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8. -
Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.
Jeng, M. Y., Dutta, R., Tan, I. T., Zhang, T. Y., & Mannis, G. N. (2020). Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies. American Journal of Hematology. -
Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Schwede, M., Tan, I. T., Atibalentja, D. F., Dickman, M. M., Rieger, K. E., & Mannis, G. N. (2020). Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm. Annals of Hematology. -
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.
Dholaria, B., Savani, B. N., Hamilton, B. K., Oran, B., Liu, H. D., Tallman, M. S., … Nagler, A. (2020). Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
Ladha, A., Mannis, G., & Muffly, L. (2020). Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. Leukemia & Lymphoma, 1–7. -
Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.
Nawas, M. T., Sheng, Y., Huang, C.-Y. Y., Andreadis, C., Martin, T. G., Wolf, J. L., … Olin, R. L. (2020). Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation. Journal of Geriatric Oncology. -
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., … Tallman, M. S. (2021). NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(1), 16–27. -
Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6. -
Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
Dutta, R., Miao, S. Y., Phan, P., Fernandez-Pol, S., Shiraz, P., Ho, D., … Zhang, T. Y. (2021). Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report. Journal of Medical Case Reports, 15(1), 170. -
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
Wang, V. E., Blaser, B. W., Patel, R. K., Behbehani, G. K., Rao, A. A., Durbin-Johnson, B., … Andreadis, C. (2021). Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discovery, 2(5), 434–449. -
The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
Sallman, D., Asch, A., Kambhampati, S., Al Malki, M., Zeidner, J., Donnellan, W., … Daver, N. (2021). The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients
Tan, I., Choi, J. H., Cunanan, K., Fronk, J., Zhang, T., Mannis, G. N., & Ramchandran, K. (2021). Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2021). Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2021). Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. -
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
Pullarkat, V., Levis, M. J., Mannis, G. N., Strickland, S. A., Lin, T. L., Faderl, S., … Erba, H. P. (2021). Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., & Liedtke, M. (2021). Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
Tan, I., Schwede, M., Phan, P., Yin, R., Zhang, T. Y., & Mannis, G. N. (2021). Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven). -
Gilteritinib Clinical Activity in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors.
Numan, Y., Abdel Rahman, Z., Grenet, J., Boisclair, S., Bewersdorf, J. P., Collins, C., … Altman, J. K. (2022). Gilteritinib Clinical Activity in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. American Journal of Hematology. -
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
On, S., Rath, C. G., Lan, M., Wu, B., Lau, K. M., Cheung, E., … Saunders, I. M. (2022). Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. British Journal of Haematology. -
Patterns and predictors of functional decline after alloHCT in older adults.
Huang, L.-W. W., Sheng, Y., Andreadis, C., Logan, A. C., Mannis, G. N., Smith, C. C., … Olin, R. L. (2022). Patterns and predictors of functional decline after alloHCT in older adults. Transplantation and Cellular Therapy. -
Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
Kennedy, V. E., Hui, G., Azenkot, T., Gaut, D., Wieduwilt, M. J., Oliai, C., … Mannis, G. N. (2022). Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia. American Journal of Hematology. -
Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial
Pullarkat, V. A., Levis, M., Mannis, G. N., Strickland, S. A., Lin, T. L., Faderl, S., … Erba, H. P. (2021). Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial. BLOOD. AMER SOC HEMATOLOGY. -
AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results.
Daver, N., Vyas, P., Kambhampati, S., Malki, M. A., Larson, R., Asch, A., … Sallman, D. (2022). AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Clinical Lymphoma, Myeloma & Leukemia, 22 Suppl 2, S253–S254. -
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
Daver, N. G., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A. S., … Sallman, D. A. (2022). Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Embedded outpatient palliative care for hematologic malignancies: Referral patterns and health care utilization.
Tsang, M., Bischoff, K. E., Schoenbeck, K. L., Berry, K., O'Riordan, D., Fakhri, B., … Rabow, M. W. (2022). Embedded outpatient palliative care for hematologic malignancies: Referral patterns and health care utilization. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
McCloskey, J. K., Pullarkat, V. A., Mannis, G. N., Lin, T. L., Strickland, S. A., Fathi, A. T., … Levis, M. J. (2022). V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
Pemmaraju, N., Kantarjian, H. M., Sweet, K. L., Wang, E. S., Senapati, J., Wilson, N. R., … Lane, A. A. (2022). North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. -
Value of embedded palliative care: outpatient palliative care and healthcare utilization for hematologic malignancies.
Tsang, M., Bischoff, K. E., Schoenbeck, K. L., Berry, K., O'Riordan, D., Fakhri, B., … Rabow, M. (2023). Value of embedded palliative care: outpatient palliative care and healthcare utilization for hematologic malignancies. Blood Advances. -
Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis
Khanna, V., Azenkot, T., Liu, S. (Q., Gilbert, J., Cheung, E., Lau, K., … Mannis, G. N. (2022). Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis. BLOOD. AMER SOC HEMATOLOGY. -
Tolerability and Efficacy of the First-InClass Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results
Daver, N., Vyas, P., Kambhampati, S., Al Malki, M., Larson, R., Asch, A., … Sallman, D. (2022). Tolerability and Efficacy of the First-InClass Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia
Gaut, D., Oliai, C., Boiarsky, J., Zhang, S., Azenkot, T., Kennedy, V. E., … Schiller, G. J. (2022). Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia. BLOOD. AMER SOC HEMATOLOGY. -
V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type
McCloskey, J., Pullarkat, V. A., Mannis, G. N., Lin, T. L., Strickland, S. A., Fathi, A. T., … Levis, M. J. (2022). V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type. BLOOD. AMER SOC HEMATOLOGY. -
The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough.
St Martin, E. C., Zhang, T. Y., & Mannis, G. N. (2023). The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough. Clinical Lymphoma, Myeloma & Leukemia. -
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Pollyea, D. A., Altman, J. K., Assi, R., Bixby, D., Fathi, A. T., Foran, J. M., … Stehman, K. (2023). Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21(5), 503–513. -
Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
Lai, C., Bhansali, R. S., Kuo, E. J., Mannis, G., & Lin, R. J. (2023). Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 43, e390018. -
Leukostasis-induced digital ischemia.
Hasty, A., Joshi, M., Lee, D., & Mannis, G. N. (2023). Leukostasis-induced digital ischemia. EJHaem, 4(2), 497–498. -
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
Khanna, V., Azenkot, T., Liu, S. Q., Gilbert, J., Cheung, E., Lau, K., … Mannis, G. N. (2023). Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. Leukemia Research, 131, 107331. -
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis, R. M., Daver, N., Altman, J. K., Komrokji, R. S., Pollyea, D. A., Badar, T., … Zeidan, A. M. (2023). Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. The Lancet. Haematology. -
Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.
Huang, L.-W. W., Shi, Y., Andreadis, C., Logan, A. C., Mannis, G. N., Smith, C. C., … Olin, R. L. (2023). Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. Journal of Geriatric Oncology, 14(8), 101623. -
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
Daver, N. G., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A. S., … Sallman, D. A. (2023). Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2202604. -
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
Gaut, D., Oliai, C., Boiarsky, J., Zhang, S., Salhotra, A., Azenkot, T., … Schiller, G. (2023). Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leukemia & Lymphoma, 1–9. -
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Ef cacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
Aldoss, I., Issa, G. C., Thirman, M., DiPersio, J., Arellano, M., Blachly, J. S., … Stein, E. M. (2023). Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Ef cacy and Safety Results from the Pivotal Augment-101 Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY. -
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju, N., Madanat, Y. F., Rizzieri, D., Fazal, S., Rampal, R., Mannis, G., … Lane, A. A. (2024). Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leukemia & Lymphoma, 1–12. -
Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the PostVenetoclax Era
St Martin, E. C., Schwede, M., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., … Mannis, G. (2023). Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the PostVenetoclax Era. BLOOD. AMER SOC HEMATOLOGY. -
Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks
Sinha, R., Schwede, M., Ben Viggiano, Kuo, D., Henry, S., Wood, D., … Zhang, T. Y. (2023). Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks. BLOOD. AMER SOC HEMATOLOGY. -
The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data
Schwede, M., Rodriguez, G., Henry, S., Wood, D., Mannis, G., Majeti, R., … Zhang, T. Y. (2023). The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data. BLOOD. AMER SOC HEMATOLOGY. -
Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations
Kuo, E., Santiago, V., Tanaka, K., Puram, V., Zhou, C., Tai, J. W., … Zhang, T. Y. (2023). Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations. BLOOD. AMER SOC HEMATOLOGY. -
Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia
Tai, J. W., Li, G., Tanaka, K., Gopakumar, J., Zhou, C., Linde, M. H., … Zhang, T. Y. (2023). Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia. BLOOD. AMER SOC HEMATOLOGY. -
Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort
Cheung, E., Schumann, C., Zhang, T. Y., Fakhri, B., Gotlib, J., Liedtke, M., … Mannis, G. (2023). Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort. BLOOD. AMER SOC HEMATOLOGY. -
Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
Gunaratne, R., Zhou, C., Tai, J. W., Schwede, M., Tanaka, K., Alkaitis, M., … Zhang, T. Y. (2023). Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML). BLOOD. AMER SOC HEMATOLOGY. -
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
Aldoss, I., Issa, G. C., Thirman, M. J., DiPersio, J., Arellano, M., Blachly, J. S., … Stein, E. M. (2023). Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study. BLOOD. AMER SOC HEMATOLOGY. -
Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients
Moscvin, M., Schwede, M., Mannis, G., & Zhang, T. Y. (2023). Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients. BLOOD. AMER SOC HEMATOLOGY. -
A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform
Wagner, J., Lacher, M. D., Gu, C. J., Leonardi, C., & Mannis, G. (2023). A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform. BLOOD. AMER SOC HEMATOLOGY. -
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Hu, X., Ediriwickrema, A., Saleem, A., Tan, B., Pemmaraju, N., & Mannis, G. N. (2024). CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leukemia Research, 139, 107479. -
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., … Fernandez-Pol, S. (2024). p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. American Journal of Clinical Pathology. -
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Issa, G. C., Aldoss, I., Thirman, M. J., DiPersio, J., Arellano, M., Blachly, J. S., … Stein, E. M. (2024). Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400826.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
- Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
- Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
- IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
- A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Practice Locations
Hematologic Cancer Program Palo Alto, CA
Palo Alto, CA
Hematologic Cancer Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(125 reviews)
Answered all my questions! Great
Dr. Mannis is very knowledgeable and experienced, I value his medical opinion and input. It has helped me make the best decisions moving forward while dealing with a complicated oncology history.
Clear, upbeat, concise. Discussed several potential treatment options, some of which he needed to discuss with my transplant doctor, Robert Lowsky.
Instructions for immediate next steps were clear, and were plans for follow-up.
Very easy to talk to.
Very personable and caring
Excellent!
The best! A wonderful doctor in all respects.
He is an exceptional doctor and extremely easy to talk to. He is patient and puts me at ease when talking to him. He answers all of my questions and I finish the call very satisfied.
It means so much that Dr. Mannis checks up on me. The Stanford standard of care is unmatched!
Very caring and listens to my questions
Dr. Mannis is fantastic
He is very kind and listens and explains the options available very well.
I think is great and answers all my questions
Caring and compassionate.
He is excellent
Thoughtful, knowledgeable provider, good at answering questions, and well prepared for my appointment which is extremely helpful and reassuring for a complex AML oncology patient like myself.
Dr. Man is was very efficient with explanation of my disease. He made me feel very comfortable, and answered my questions.
I am very impressed with Dr. Mannis. He is very compassionate, professional, and caring.
Dr. Man is is thorough into the point, he does not mince words he tells you exactly what’s going to happen and gives you a very concise and accurate description of all the procedures!
Dr. Mannis is WONDERFUL! He listens, really listens, and is very compassionate, empathetic and intelligent. I have felt completely comfortable with Dr. Mannis at the helm of my care from the first time I spoke with him. He immediately put me and my family at ease in what was a very stressful and scary time. And he cured me! He is wonderful and Stanford (and me) are lucky to have him.
Very concerned and very informative. I felt very comfortable, with the knowledge he has.
He was very caring, answered all my concerns.
One of my favorite doctors of all time. And I’ve seen many.
Very caring, Dr Mannis addressed all my concerns.
Dr Mannis is an excellent doctor.
Dr. Mannis is the best!!
Dr Mannis is a true humanitarian -- his concern for me, as a patient, was obvious from the outset, yet he was quite open and forthcoming in projecting my potential future outcomes.
It was reassuring to have a Dr like Dr Mannis available for my care.
Very charismatic and knowledgeable.
Dr Mannis is excellent!
Thank you for a thorough review. I did not feel rushed and all questions were answered with a lot of patience. Thank you for your compassion.
Very careful physician
Great doctor
Very friendly. Very knowledgeable and easy to talk to.
Dr. Mannis is an excellent doctor. He really clearly outlined what was going on with my condition and what I could expect in the future. He was so extremely sympathetic and helpful.
Excellent!
The best!
Very helpful and understanding would highly recommend him to others
He is fantastic. I owe him my life. I would recommend him to anyone to be treated for blood cancer
He’s wonderful, knowledgeable, engaging, easy to understand, and has a great team that he works with.
Amazing person, amazing doctor
Incredibly helpful
Superb doctor !
Dr. Mannis is the best Dr. we ever seen. He treated patients like his family member and answered questions throughly when we have. We really appreciate his efforts in treating my disease .
Great easy to talk to amazing staff
He is easy to talk to and takes his time to explain .things.
Positive attitude. Answers questions honestly and directly. I trust his judgement.
I can see why Dr. Mannis does many interviews on YouTube, his bedside manner is incredible and a pleasure to listen to.
He’s awesome! Knowledgeable, informative, friendly and professional.
Dr. Mannis is an excellent doctor and I would recommend him to anyone going through what I have been going through.
Very thorough and involved with my situation.
He is the best!
Dr. Mannis is an awesome doctor. Very knowledgeable, professional, and friendly.
Visit was efficiently and professionally operated
Excellent communicator and very knowledgable
He’s a great healthcare provider and a nice person.
Dr. Mannis continues to be engaging and warm as well as extremely knowledgeable. I feel completely confident in my care with Dr. Mannis at the helm.
Wonderful doctor
I feel reassured and more knowledgeable after our visits.
Dr Mannis and staff are exceptional
Thank you, Dr. Mannis for everything.
Thorough and concise.
None. The doctor clearly knew my chart and medical treatment history.
I think it is a great doctor
Excellent doctor
Outstanding, professional, compassionate and incredibly knowledgeable specialist whom I am thrilled to now be under the care of!
A truly expert and humane doctor.
It is alwsys a pleasure seeing Dr. Mannis. He is warm, professional, personal & an excellent doctor.
Excellent listener and considerate demeanor.
First of all, I want to say that Dr. Mannis is the best out of the best. He is always nice, professional and caring; I am very lucky to have him as my doctor. Both of my husband and I trust him deeply. He is truly fostering empathy, compassion, kindness and hope! Thank you so much Dr. Mannis!
I found him to be very informative and professional
Dr. Mannis is a wonderful doctor. I appreciate everything he has done for me.
Dr. Mannis is as good as it gets in his field. Appreciated his realistic opinion about the risks involved in a transplant situation.
In my experience (73 years) Dr Mannis ranks up there with the best doctors I have dealt with. I really can’t say enough about his expertise as an MD and his delightful personality.
Overall, great doctor…
He is great
The best care I can ever imagine. Thank you.
Talk to Mannis is an exceptional position and individual. He cares for his patients.
Excellent experience with dr. Mannis and rest of overall treatment at Stanford.
I have confidence in him. Good man and good doctor.
He is a great doctor. Very knowledgeable and quite capable of answering general and very specific ones too. Very few doctors are as approachable as he always is.
I have been seeing the Doctor for a little over 3 years. He "designed" my program and so far it has been wonderful. My leukemia seems to be in remission. (although we won't know unless we do a biopsy) He is very patient and understanding and I still remember our initial visit and how wonderful and patient he was to explain what was going to happen to me with my Leukemia. Super sharp !!
The BEST!!!!
Dr. Mannis was very informative and explained things well. We felt comfortable talking with him and greatly appreciate how much he's working with our local oncology doctor.
Dr. Mannis always shows concern about my well-being and is very caring. I enjoy our telehealth appointments.
He is fantastic. Saved my life!!!
Excellent physician. Always interested in my overall condition as well as the specific condition that is under treatment. Wonderful sense of humor. Encouraging, caring and focused on welfare.
The staff at the infusion center are knowledgeable, thorough, and very personable. They make it not only bearable, but even fun.
I feel that Dr. Mannis tailored my treatment to meet my needs and was very sensitive to my situation and the urgency of it. I am so very grateful for him and his team and look forward to starting treatment soon and with confidence even though he was clear that it would not be easy. At least it’s a chance! He gave me hope.
Explained everything well.
Truly professional, empathetic, honest and upfront. Medically explained everything very well. I'll be seeing him tomorrow
Great Dr for my needs.
When I was diagnosed with AML, Dr. Mannis was my first contact at Stanford. After explaining the medical treatment regime, he then took the time to discuss with my wife and I the probability of success, medical implications, and end-of-life options to consider.
The clear, compassionate explanation of what lay ahead greatly reduced my anxiety. Throughout the year-long procedure, Dr. Mannis stayed in contact and even visited during a chemo session.
Now, that I have been leukemia free with no GVHD for more than 2 years, Dr. Mannis still personally follows up to check on my medical and psychological process.
Dr. Mannis is an exceptional physician, and human being, who demonstrates genuine concern for his patients.
Dr. Mannis is always warm, compassionate, friendly and a really wonderful doctor. He let's me ask silly questions and never seems annoyed by them. It's always a pleasure visiting with him and I trust him completely.
Appreciated Dr. Mannis's time today.
Excellent Hematologist. And I've had experience with many.
Hear Mannis is very easy to talk to. He is very caring and informative.
He’s great!
I am very lucky to have him on my case.
Dr. Mannis is absolutely the best!!!!
Very professional and well versed on where we are with my case and protocols.
Dr. Mannis is very likeable, easy to talk to, compassionate and seems like a really nice person. I always look forward to seeing him and know that he will be honest and considerate even when it's bad news.
Dr Mannis and his team are excellent. They take the time to listen to you, answer all your questions and to make you feel comfortable with treatment options.
Very pleased with him.
excellent
I am very happy to have my care in his hands.
I have found him to be an excellent MD and a compassionate human being.
Absolutely wonderful physician
Pleasure to speak to Dr Mannis
Over a period of 2 years plus association, Dr. Gabriel Mannis has been not just the medical professional / adviser but friend, philosopher and guide. We will not forget him.
Very nice and generous Doctor.
He's great.
Thank you so much for your hard work & kindness :)
This is my first time with only few minutes of video call with Dr. Mannis, so far so good and Dr. Mannis did clearly spoke and explained everything in this call.
Dr. Mannis is extremely focused on my care and is so professional in his interaction with me. He takes the time to answer all of my questions in a caring way.
His team is also doing a great job with making sure that our communications are in sync.
Thank you to everyone!
Dr. Mannis is FABULOUS! He saved my life!
Excellent MD
He is wonderful. Great bedside manner, seems like he really cares, very genuine and knowledgeable. And he cured me! Cannot say enough wonderful things about Dr. Mannis. Thank you!!!
Dr Mannis is very knowledgeable and clear with his plans for treatment
Dr Mannis came very highly recommended by my local oncologist Dr James Link, who admires Dr Mannis very much. Dr Link is leaving the local practice in 6 weeks, and I am sure that he felt better having Dr Mannis take over my case than any of the other local oncologists.
I was impressed that he pinpointed a big issue with treating my AML, being that I have a problem with normal living in that my heartbeat races with the slightest expenditure of energy. That will have to be dealt with before Dr Mannis can use any aggressive action on the cancer. His parting words to me were, "We will see how tough you are".
Dr Link was aware of the heart complication but could not get an appointment with a cardiologist for me as that specialty is locally short staffed. Dr Mannis has made it Step 1 to get me seen by a cardiologist up at Stanford.
I would like to know if I may communicate directly with Dr Mannis via text or email as I have been able to do with Dr Link.
He is an extremely knowledgeable physician with excellent interpersonal skills. I am lucky to have him as my doctor.
An excellent, knowledgeable kind Doctor.
Dr. Mannis is very professional. He keeps on top of treatment options and answers all of my questions. He shows great compassion towards my best interest regarding my overall health and quality of life. I am happy that he is my doctor.
Best doctor I’ve dealt with. Makes me feel special and takes time to explain any questions I might have. Never feel rushed. Wish more doctors and their staff were the same!!!
Very informative
I feel very confident in Dr. Mannis
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records